Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
…, G Roubaud, S Pernot, M Cabart, F Chomy… - Nature Cancer, 2021 - nature.com
Only a minority of patients derive long-term clinical benefit from anti-programmed cell death
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies…
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies…
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer
…, N Houédé, A Floquet, F Chomy… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Objective factors for making choices about the treatment of elderly patients with
cancer are lacking. This investigation aimed to help physicians select appropriate treatments …
cancer are lacking. This investigation aimed to help physicians select appropriate treatments …
Is there a role for percutaneous ablation for early stage lung cancer? What is the evidence?
…, M Cazayus, S Cousin, M Cabart, F Chomy… - Current Oncology …, 2021 - Springer
Purpose of Review For patients with early stage non-small-cell lung cancer (NSCLC), thermal
ablation (TA) has become in the least two decades an option of treatment used worldwide …
ablation (TA) has become in the least two decades an option of treatment used worldwide …
[HTML][HTML] Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial
…, L Cany, S Lavau-Denes, N Houede, F Chomy… - PloS one, 2014 - journals.plos.org
Objective We tested the effect of dietary advice dedicated to increase intake in older patients
at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality. …
at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality. …
[HTML][HTML] Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial
J Palussière, F Chomy, M Savina, F Deschamps… - Journal of …, 2018 - Springer
Background A prospective multicenter phase II trial to evaluate the survival outcomes of
percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung …
percutaneous radiofrequency ablation (RFA) for patients with stage IA non-small cell lung …
[HTML][HTML] Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
…, G Roubaud, M Cabart, F Chomy, F Le Loarer… - Annals of …, 2022 - Elsevier
Background The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the
systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive …
systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive …
Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous
thermal ablation (TA) has proven feasibility, good local control and good tolerance in …
thermal ablation (TA) has proven feasibility, good local control and good tolerance in …
Percutaneous lung thermal ablation of non-surgical clinical N0 non-small cell lung cancer: results of eight years' experience in 87 patients from two centers
…, P Lagarde, A Aupérin, F Deschamps, F Chomy… - Cardiovascular and …, 2015 - Springer
Purpose To evaluate the survival outcomes of percutaneous thermal ablation (RFA + microwaves)
for patients presenting N0 non-small-cell lung cancer (NSCLC) ineligible for surgery. …
for patients presenting N0 non-small-cell lung cancer (NSCLC) ineligible for surgery. …
[HTML][HTML] Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
…, C Pouypoudat, D Barbolosi, F Barlesi, F Chomy… - Scientific Reports, 2019 - nature.com
… the method of characteristics, one can derive the following relationship between N and f: …
Of particular interest is the number of visible BMs \(f(t,{S}_{vis})\) with S vis the minimal visible …
Of particular interest is the number of visible BMs \(f(t,{S}_{vis})\) with S vis the minimal visible …
Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 …
…, H Morel, E Pichon, A Cortot, J Otto, F Chomy… - Clinical Cancer …, 2022 - AACR
Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized
the approach to non–small cell lung cancer (NSCLC) treatment in the era of precision …
the approach to non–small cell lung cancer (NSCLC) treatment in the era of precision …